Castration-resistant Prostate Cancer Clinical Trials in Boston, Massachusetts
18 recruitingBoston, Massachusetts
Showing 1–18 of 18 trials
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Prostate Cancer Clinical Trials Consortium126 enrolled5 locationsNCT06844383
Recruiting
Phase 1Phase 2
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 1
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Urothelial CarcinomaRenal Cell CarcinomaCastration-resistant Prostate Cancer
Deciphera Pharmaceuticals, LLC60 enrolled5 locationsNCT06966024
Recruiting
Phase 1
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo60 enrolled19 locationsNCT07244341
Recruiting
Phase 1
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
AstraZeneca136 enrolled16 locationsNCT06879041
Recruiting
Phase 1
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate Cancer (Adenocarcinoma)mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited67 enrolled8 locationsNCT06801236
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Colorectal, CancerGastric CancerBiliary Tract Cancer+4 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 1
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb140 enrolled8 locationsNCT06067841
Recruiting
Phase 4
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-Resistant Prostate Carcinoma
Brigham and Women's Hospital30 enrolled2 locationsNCT06099093
Recruiting
Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-Resistant Prostatic Cancer
Janux Therapeutics272 enrolled35 locationsNCT05519449
Recruiting
Phase 1Phase 2
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals345 enrolled21 locationsNCT03972657
Recruiting
Phase 1
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Metastatic Breast CancerAdvanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)+3 more
Olema Pharmaceuticals, Inc.180 enrolled8 locationsNCT06784193
Recruiting
Phase 2
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
PSMA PET-Positive Castration-Resistant Prostate Cancer
Convergent Therapeutics60 enrolled9 locationsNCT06549465
Recruiting
Phase 1
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer
Prostate CancerMetastatic Prostate CancerMetastatic Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute37 enrolled3 locationsNCT06303713
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776